RecruitingNot ApplicableNCT05268120

MRSA Decolonization in Complicated Carriage

MRSA Decolonization in Complicated Carriage - Cluster Randomized Trial

Sponsor

Leiden University Medical Center

Enrollment

211 participants

Start Date

Jul 25, 2022

Study Type

INTERVENTIONAL

Conditions

MRSA

Summary

Multicenter open-label cluster randomized controlled trial determining the superiority of doxycycline-rifampicin compared to trimethoprim-rifampicin for the decolonization treatment of complicated MRSA carriership.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called doxycycline 200 mg q.d. - rifampicin 600mg b.i.d. and a drug called trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d. for people with mrsa. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdoxycycline 200 mg q.d. - rifampicin 600mg b.i.d.

Both first choice treatments in Dutch guideline for MRSA decolonization

DRUGtrimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.

Both first choice treatments in Dutch guideline for MRSA decolonization

Locations(1)

LUMC

Leiden, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05268120

Related Trials

Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC

NCT047931524 locations